[go: up one dir, main page]

WO2001066110A3 - METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA2 INHIBITORS - Google Patents

METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA2 INHIBITORS Download PDF

Info

Publication number
WO2001066110A3
WO2001066110A3 PCT/US2001/000007 US0100007W WO0166110A3 WO 2001066110 A3 WO2001066110 A3 WO 2001066110A3 US 0100007 W US0100007 W US 0100007W WO 0166110 A3 WO0166110 A3 WO 0166110A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
renal dysfunction
spla2 inhibitors
spla2
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/000007
Other languages
French (fr)
Other versions
WO2001066110A2 (en
Inventor
William Louis Macias
Vincent Phillip Meador
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to AU2001229252A priority Critical patent/AU2001229252A1/en
Priority to EP01956186A priority patent/EP1265607A2/en
Priority to JP2001564763A priority patent/JP2003525901A/en
Publication of WO2001066110A2 publication Critical patent/WO2001066110A2/en
Publication of WO2001066110A3 publication Critical patent/WO2001066110A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

A method is disclosed for the treatment of of the symptoms associated with renal dysfunction by administering to an animal in need thereof a therapeutically effective amount of a sPLA2 inhibitor, such as a 1H-indole-3-glyoxylamide.
PCT/US2001/000007 2000-03-09 2001-01-16 METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA2 INHIBITORS Ceased WO2001066110A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2001229252A AU2001229252A1 (en) 2000-03-09 2001-01-16 Method for the treatment of renal dysfunction with spla2 inhibitors
EP01956186A EP1265607A2 (en) 2000-03-09 2001-01-16 METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA 2 INHIBITORS
JP2001564763A JP2003525901A (en) 2000-03-09 2001-01-16 Method for treating renal dysfunction with sPLA2 inhibitor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18803900P 2000-03-09 2000-03-09
US60/188,039 2000-03-09

Publications (2)

Publication Number Publication Date
WO2001066110A2 WO2001066110A2 (en) 2001-09-13
WO2001066110A3 true WO2001066110A3 (en) 2002-04-25

Family

ID=22691545

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/000007 Ceased WO2001066110A2 (en) 2000-03-09 2001-01-16 METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA2 INHIBITORS

Country Status (4)

Country Link
EP (1) EP1265607A2 (en)
JP (1) JP2003525901A (en)
AU (1) AU2001229252A1 (en)
WO (1) WO2001066110A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964596B2 (en) * 2008-03-07 2011-06-21 Allergan, Inc. Therapeutic compounds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991006537A2 (en) * 1989-10-27 1991-05-16 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole- alkanoic acid derivatives as inhibitors of pla2 and lipoxygenase
EP0675110A1 (en) * 1994-04-01 1995-10-04 Eli Lilly And Company 1H-Indole-3-glyoxylamide sPLA2 inhibitors
WO1997009308A1 (en) * 1995-09-01 1997-03-13 Eli Lilly And Company Indolyl neuropeptide y receptor antagonists
EP0799836A1 (en) * 1994-12-29 1997-10-08 Yamanouchi Pharmaceutical Co. Ltd. Novel monoclonal antibody having inhibitory effect on type ii phospholipase a2 and protein containing a part of the same
WO1999044604A1 (en) * 1998-03-03 1999-09-10 Shionogi & Co., Ltd. Pharmaceutical compositions containing the phospholipase inhibitor sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl]oxy]acetate

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991006537A2 (en) * 1989-10-27 1991-05-16 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole- alkanoic acid derivatives as inhibitors of pla2 and lipoxygenase
EP0675110A1 (en) * 1994-04-01 1995-10-04 Eli Lilly And Company 1H-Indole-3-glyoxylamide sPLA2 inhibitors
EP0799836A1 (en) * 1994-12-29 1997-10-08 Yamanouchi Pharmaceutical Co. Ltd. Novel monoclonal antibody having inhibitory effect on type ii phospholipase a2 and protein containing a part of the same
WO1997009308A1 (en) * 1995-09-01 1997-03-13 Eli Lilly And Company Indolyl neuropeptide y receptor antagonists
WO1999044604A1 (en) * 1998-03-03 1999-09-10 Shionogi & Co., Ltd. Pharmaceutical compositions containing the phospholipase inhibitor sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl]oxy]acetate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KAWAUCHI, Y. ET AL: "Role of type II Phospholipase A2 (plA2) in ischemic acute renal failure in rats", MOLECULAR BIOLOGY OF THE CELL, vol. 7, no. suppl, 1996, pages 143a, XP001000916 *

Also Published As

Publication number Publication date
WO2001066110A2 (en) 2001-09-13
EP1265607A2 (en) 2002-12-18
AU2001229252A1 (en) 2001-09-17
JP2003525901A (en) 2003-09-02

Similar Documents

Publication Publication Date Title
WO2004054505A3 (en) Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors
WO2003002531A3 (en) Fluoropyrrolidines as dipeptidyl peptidase inhibitors
WO2003002553A3 (en) Fluoropyrrolidines as dipeptidyl peptidase inhibitors
EP1602370A3 (en) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
WO2002060869A3 (en) Use of p38 inhibitors for the treatment of inflammation-enhanced cough
AU3772000A (en) Selective inhibition of cyclooxygenase-2
WO2001056573A8 (en) Use of cox-2 inhibitors as gastroprokinetics
WO2005046657A3 (en) Use of an inhibitor of csf-1 activity for the treatment of inflammatory bowel disease
CA2383785A1 (en) Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
HK1043303A1 (en) Use of apomorphine in the manufacture of a medicament for the treatment of organic erectile dysfunction in males
EP1099442A3 (en) Methods of administering apo B-secretion/MTP inhibitors
WO2006081431A3 (en) Compounds for treating inflammatory and demyelinating diseases
EA200100930A1 (en) METHOD OF TREATMENT COPD
HK1051319A1 (en) Method and compositions for treating an inflammatory disease
WO2006009718A3 (en) Methods for treating or preventing erectile dysfunction or urinary incontinence
WO2001066110A3 (en) METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA2 INHIBITORS
WO2007092436A3 (en) Compounds for treating inflammatory disorders, demyelinating disorders and cancers
WO2007149543A3 (en) Scar treatment using protein phosphatase inhibitors
EA200001140A1 (en) COMPOUNDS INHIBITORS sPLA2 FOR THE TREATMENT OF DISEASE
WO2001055108A3 (en) Use of spl a2 inhibitors for the treatment of inflammation
SG170830A1 (en) Renin inhibitors for the treatment of hypertension
WO2001087281A3 (en) Method for enhancing cognitive function
WO2004060878A3 (en) Inhibitors of phosphatases
WO2005041886A3 (en) Methods for generating or increasing revenues related to pain inhibitor commerce

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10203436

Country of ref document: US

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 564763

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001956186

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001956186

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001956186

Country of ref document: EP